Prosecution Insights
Last updated: November 17, 2026
Application No. 18/026,128

ASPOROGENOUS BACTERIA AND USES THEREOF AS A FEED INGREDIENT

Non-Final OA §103§112
Filed
Mar 14, 2023
Priority
Sep 16, 2020 — provisional 63/079,164 +1 more
Examiner
GROOMS, TIFFANY NICOLE
Art Unit
1637
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Superbrewed Food Inc.
OA Round
3 (Non-Final)
58%
Grant Probability
Moderate
3-4
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
108 granted / 186 resolved
-1.9% vs TC avg
Strong +46% interview lift
Without
With
+46.4%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
55 currently pending
Career history
249
Total Applications
across all art units

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Application Status The Amendments and Remarks filed 16 September 2026 in response to the Office Action 30 June 2026 are acknowledged and have been entered. Claims 1 and 30 are amended. Claims 2-5, 12, 14-15 and 17-29 have been cancelled. Claims 1, 6-11, 13, 16 and 30-34 are pending and being examined on the merits. Any rejections or objections not reiterated herein have been overcome by applicant’s claim amendments. The claims have been searched and reconsidered for allowance, and new objections and rejections are set forth below partially in view of the new claim amendments. Priority This application is a 371 PCT of IB2021/058282 filed 08/12/2021 which claims priority to application 63079164 filed 9/16/2020. Claim Objections Claims 13 and 30 are objected to because of the following informalities: Claims 11 and 13 recites “ resulting from a single point mutation” and “wherein said point mutation is a cytosine (C) to thymine (T) mutation”, respectively; whereas claim 1 introduces a “single base pair mutation” and does not expressly introduce the term “point mutation.” Because the intended referent is reasonably apparent and “point mutation” in claims 11 and 13 is referring to the “single base pair mutation” in claim 1, claims 11 and 13 are objected to under 37 CFR 1.75 as being a substantial duplicate of claim 1 and 6, respectively. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 608.01(m). Claim 30: Step (c) presently recites: “maintaining said culture comprising said C. tyrobutyricum bacterium having said single base pair mutation in an exponential growth phase wherein said culture at least partially comprising an asporogenous strain of C. tyrobutyricum is produced.” The phrase “wherein said culture at least partially comprising ... is produced” is grammatically defective and obscures the relationship between maintaining the culture and producing the culture containing the asporogenous strain. It is suggested that step (c) be amended to read: “maintaining said culture comprising said C. tyrobutyricum bacterium having said single base pair mutation in an exponential growth phase, thereby producing a culture at least partially comprising an asporogenous strain of C. tyrobutyricum;”. Claim 30 recites periods in the body of the claim It is suggested that each step should be designated as (a) vs. a. Each claim must start with a capital letter and end with a period, and periods may not be used elsewhere in the claims except for abbreviations See MPEP § 608.01(m). Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 8. 9, and 11 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 8 recites that “said mutation is within a DNA-binding domain.” The antecedent “said mutation” is the “single base pair mutation” recited in claim 1, i.e., a mutation at the nucleotide level in a gene. A DNA-binding domain, however, is ordinarily a structural or functional region of the protein encoded by the gene. Thus, it is unclear what relationship claim 8 requires between the nucleotide mutation and the protein DNA-binding domain. Specifically, it is unclear whether claim 8 requires (i) that the single-base-pair mutation occur within the portion of the gene encoding the DNA-binding domain, (ii) that the mutation alter an amino acid located within the DNA-binding domain, or (iii) that the mutation cause premature termination such that all or part of the DNA-binding domain is absent from the resulting protein. These interpretations impose different structural requirements on the claimed bacterium. Although the specification states that a mutation in spo0A may be “within a DNA-binding domain” [0046] and separately describes a truncated transcription factor devoid of an active DNA-binding domain [0048], those disclosures do not resolve which of the foregoing relationships is required by the language of claim 8. Accordingly, the metes and bounds of claim are not reasonably certain. Claim 9 recites “wherein said mutation is an amino acid residue that interacts with DNA.” The antecedent “said mutation” in claim 1 is a single-base-pair mutation in a gene. A base-pair mutation is an alteration of a nucleotide sequence and cannot itself be an amino acid residue. Accordingly, it is unclear whether claim 9 requires (i) a nucleotide mutation within a codon encoding an amino acid residue that interacts with DNA, (ii) an amino acid substitution at a DNA-interacting residue, or (iii) a nucleotide mutation producing premature termination that eliminates a DNA-interacting residue or region. These interpretations impose materially different requirements. The specification does not cure the ambiguity. Paragraph [0047] describes “a substitution or deletion of at least one amino acid that interacts with DNA,” whereas paragraphs [0048]–[0049] separately describe a single point mutation producing a truncated transcription factor. Example 2 describes the C475T nucleotide substitution producing a premature termination codon. Claim 9 does not state which of these relationships is intended.’ The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1, 6-11, 13, 16 and 30-34 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claims 1 and 30 are directed to an isolated mutant bacteria strain comprising a gene “wherein said gene comprises a nucleic acid sequence of SEQ ID NO: 1” and encodes a truncated transcription factor. The recitation of “a nucleic acid sequence of SEQ ID NO: 1” encompasses a subsequence comprising two or more consecutive nucleotides of the identified SEQ ID NO. rather than requiring the complete nucleotide sequence identified by that SEQ ID NO. As a result, the claims encompass a genus vastly broader than the particular sequence of SEQ ID NO: 1 that encodes a truncated transcription factor. The specification teaches that SEQ ID NO: 1 is the nucleic acid sequence of spo0A in ASM#19 [0015]. The specification does not provide a representative number of species across the much broader genus encompassed by the claims, nor does it identify structural characteristics common to substantially all nucleic acids containing or sharing identity with any two-or-more nucleotide subsequence of the disclosed SEQ ID NO: 1 Possession of the disclosed complete nucleic acid sequence of SEQ ID NO: 1 which encodes a truncated transcription factor does not reasonably demonstrate possession of the vastly large genus of nucleic acids that happened to contain, or have sequence to, a short subsequence thereof as these subsequences may also occur in unrelated nucleic acids that would not necessarily result in a truncated transcription factor. Accordingly, the specification does not demonstrate that the Applicant was in possession of the full genus mutant bacterium encompassed by the claims. Dependent claims 6-11, 13, 16 and 33-34 do not limit further limit the sequence to SEQ ID NO: 1, a particular fragment, or a particular identity of SEQ ID NO: 1 and are hereby similarly rejected. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 6-8, 10, 11, and 13 are rejected under 35 U.S.C. 103 as being unpatentable over NCBI Reference Sequence: NZ_APMH01000026.1 (Accession NZ_APMH01000026 Region: 51561..52344; 4/1/2017) in view of Blanchard (US 2010/0105114 Al), Kudoh (Kudoh et al. Proc. Nadl. Acad. Sci. USA Vol. 82, pp. 2665-2668, May 1985), Connor (Connor et al. Scientific Reports 9.1 (2019): 13722), Minton (WO2020/157487 A2) and Hatt and Youngman (Hatt and Youngman. Journal of Bacteriology 182.24 (2000): 6975-6982) as evidenced by Lewis (Lewis et al. Molecular Microbiology (2000) 38(2), 198-212), UniProtKB/Swiss-Prot: P06534.1 (2017) and UniProtKB/Swiss-Prot: P52934.2 (2017). Regarding claim 1, the NCBI Reference Sequence: NZ_APMH01000026.1 discloses the genomic sequence of Clostridium tyrobutyricum DSM 2637, also designated ATCC 25755, including the wild-type spo0A coding sequence [NZ_APMH01000026.1; insert coding-sequence coordinates and strand]. The wild-type coding sequence contains the glutamine codon CAA at codon 159, corresponding to nucleotides 475–477, numbered from the translation-initiation codon. Comparison with the claimed SEQ ID NO:1 establishes that SEQ ID NO:1 corresponds to the first 477 nucleotides of this wild-type coding sequence except for substitution of thymine for cytosine at nucleotide 475. This substitution converts CAA to the premature termination codon TAA and would terminate translation after 158 amino acids [coding-sequence nucleotides 1–477; instant application, SEQ ID NO:1]. This comparison identifies the structural difference between the claimed sequence and the prior-art sequence. The NCBI Reference Sequence: NZ_APMH01000026.1 does not expressly disclose the C475T mutation or an isolated asporogenous strain containing that mutation and encoding the resulting truncated transcription factor. Blanchard teaches producing modified Clostridium strains having reduced sporulation activity by modifying genes involved in sporulation. Blanchard expressly identifies point mutations and codon substitutions as means of modifying such genes and further identifies premature stop codons as mutations capable of reducing their activity [[0010]–[0011], [0062]]. Blanchard also identifies Spo0A as a phosphorylation-activated transcription factor and describes identification of its clostridial homolog through sequence comparison [[0123]]. Connor teaches nonsporulating C. difficile isolates having nonsense mutations in spo0A. One isolate contains a stop codon at residue 7, whereas another contains stop codons at residues 162 and 227. Connor explains that the stop at residue 162 would permit expression of the N-terminal domain while eliminating the C-terminal domain responsible for DNA binding and transcription activation [p. 5, paragraphs 1-3; p. 7, Fig. 9]. The nonsporulating isolates yielded no viable colonies following alcohol-shock treatment, indicating the absence of spores under the tested conditions [p. 3, paragraphs 3]. Kudoh demonstrates that a single C-to-T substitution in spo0A can introduce premature termination. Specifically, substitution at nucleotide +184 converts the glutamine codon CAG at residue 62 into the termination codon TAG [p. 2667-2668, col. 1, Fig. 4A]. Hatt and Youngman distinguish the larger C-terminal effector domain of Spo0A from its smaller DNA-recognition region, identifying a putative helix-turn-helix region at residues 198–218 in B. subtilis Spo0A [Fig. 1A–B]. Hatt and Youngman teaches that the C-terminal 113 residues are known to contain the DNA-binding activity of Spo0A [abstract]. Hatt and Youngman teaches that the C-terminal half of Spo0A is highly conserved among species of endospore-forming Bacillus and Clostridium and encodes a putative helix-turn-helix DNA-binding domain [abstract]. Hatt and Youngman teaches that the R214G and R214A mutations abolished both DNA binding and transcriptional activation. Regarding claim 1, it would have been obvious to a person of ordinary skill in the art before the effective filing date to introduce a single-base-pair nonsense mutation into the known C. tyrobutyricum spo0A sequence to produce an asporogenous strain. Blanchard provides an express reason to introduce premature termination into a sporulation-associated gene to reduce its activity, while Connor identifies Spo0A truncation before its C-terminal DNA-binding region as a mechanism associated with a nonsporulating clostridial phenotype. Kudoh further demonstrates the suitability of a single C-to-T substitution for introducing a termination codon into spo0A. In selecting a nonsense-mutation site, the artisan would have considered codons in the known sequence that could be converted to termination codons while preventing expression of the downstream DNA-recognition region. The CAA codon at position 159 provides such a single-substitution target. Alignment of the translated C. tyrobutyricum spo0A sequence disclosed in NCBI Reference Sequence NZ_APMH01000026.1 (protein WP_017895576.1) with B. subtilis Spo0A (UniProt P06534) places C. tyrobutyricum Q159 opposite B. subtilis A155, within the larger C-terminal effector domain. The conserved helix-turn-helix DNA-recognition region identified at B. subtilis residues 198–218 maps to C. tyrobutyricum residues 202–222 [Fig. 1A; accompanying sequence alignment]. An independent alignment with B. stearothermophilus Spo0A (UniProt P52934; PDB 1FC3) places C. tyrobutyricum Q159 opposite A147, likewise within the experimentally characterized C-terminal domain of Lweis [p. 199, “Structure solution and overall structure”; Fig. 1]. Accordingly, conversion of C. tyrobutyricum codon 159 from CAA to TAA by the C475T substitution terminates translation after residue 158, preventing expression of the entire downstream DNA-recognition region at residues 202–222. This alignment supports loss of that region from the encoded protein. Connor’s residue-162 truncation supports the functional consequence of truncating Spo0A before that region; the proposed modification does not depend merely on numerical proximity between residues in different species. The artisan would therefore have had reason to select the C475T substitution, with a reasonable expectation that the resulting loss of the downstream DNA-recognition region would disable Spo0A-dependent initiation of sporulation and produce an asporogenous strain. The resulting gene would contain the nucleotide sequence of SEQ ID NO:1 and encode a truncated Spo0A transcription factor comprising 158 amino acids. Retention of genomic DNA downstream of the premature termination codon would not prevent the gene from comprising SEQ ID NO:1. Accordingly, the proposed modification would provide the isolated asporogenous C. tyrobutyricum strain recited in claim 1. Regarding claims 6 and 13, the modification explained in the rejection of claim 1 replaces cytosine with thymine at nucleotide 475 of the spo0A coding sequence. Accordingly, the proposed modification expressly provides the claimed cytosine-to-thymine single-base-pair mutation [coding-sequence nucleotide 475; comparison with SEQ ID NO:1]. Kudoh further demonstrates introduction of a premature termination codon into spo0A through a single cytosine-to-thymine substitution [p. 2667, Fig. 4A]. Regarding claim 7, the proposed C475T substitution converts the glutamine codon CAA at coding-sequence nucleotides 475–477 into the termination codon TAA. Thus, the single-base-pair mutation creates a stop codon as claimed. Blanchard expressly identifies premature stop codons as mutations suitable for reducing the activity of sporulation-associated genes [0062]. Regarding clam 8, the nucleotide substitution occurs in the portion of spo0A encoding the C-terminal DNA-binding/effector domain. Hatt and Young distinguish this larger effector domain from the smaller DNA-recognition located within it [Fig. 1A-B]. According the C475T substitution described above occurs within the coding region for the DNA-binding domain, although the resulting premature termination prevents expression of the downstream DNA-recognition region. Regarding claim 10, Connor explains that premature termination of Spo0A at residue 162 would eliminate the C-terminal domain responsible for DNA binding and transcription activation [p. 5, paragraphs 1-3; p. 7, Fig. 9]. Hatt and Youngman identify a smaller DNA-recognition region within the larger C-terminal effector domain [Fig. 1A–B]. For the structural reasons explained in the rejection of claim 1, the proposed C475T substitution would terminate translation after residue 158 and prevent expression of the downstream DNA-recognition region. Thus, the resulting truncated transcription factor would therefore lack an active DNA-binding domain. Regarding claim 11, the truncated transcription factor of claim 10 results from the single C475T point mutation in the spo0A gene encoding that protein. No additional mutation is required to create the premature termination codon or terminate translation after residue 158. Thus, the modification explained for claims 1 and 10 also provides the additional limitation of claim 11. Claim 16 is rejected under 35 U.S.C. 103 as being unpatentable over NCBI Reference Sequence: NZ_APMH01000026.1 (Accession NZ_APMH01000026 Region: 51561..52344; 4/1/2017) in view of Blanchard (US 2010/0105114 Al), Kudoh (Kudoh et al. Proc. Nadl. Acad. Sci. USA Vol. 82, pp. 2665-2668, May 1985), Connor (Connor et al. Scientific Reports 9.1 (2019): 13722) and Hatt and Youngman (Hatt and Youngman. Journal of Bacteriology 182.24 (2000): 6975-6982) as evidenced by Lewis (Lewis et al. Molecular Microbiology (2000) 38(2), 198-212), UniProtKB/Swiss-Prot: P06534.1 (2017) and UniProtKB/Swiss-Prot: P52934.2 (2017) as applied to claim 1, and further in view of Tracy (WO 2019/200103). The teachings of NCBI Reference Sequence: NZ_APMH01000026.1, Blanchard, Kudoh, Connor and Hatt and Youngman are discussed above as applied to claim 1 and similarly apply to claim 16. These references do not expressly teach using that strain as a food ingredient. Tracy teaches a feed ingredient comprising at least 20% by weight C. tyrobutyricum and further teaches embodiments in which the C. tyrobutyricum is genetically modified. [[003]; claims 1 and 19.] The reference further teaches producing the feed ingredient by culturing C. tyrobutyricum to form cell mass and mechanically separating, washing, drying, pulverizing, extruding, or pelletizing the cell mass [[008], [0032]–[0034]]. It would have been obvious to a person of ordinary skill in the art to employ the asporogenous C. tyrobutyricum strain rendered obvious by the combination as applied to claim 1 as the C. tyrobutyricum component of the feed ingredient taught by Tracy. The skilled artisan would have been motivated to do so because Tracy expressly contemplates genetically modified C. tyrobutyricum as the bacterial component of such feed ingredients and teaches harvesting and processing C. tyrobutyricum cell mass for that purpose. Substitution of the known genetically modified/asporogenous strain for the C. tyrobutyricum biomass already used in the prior-art feed ingredient would have represented the predictable use of the modified strain in an expressly taught end use. Claims 30-34 are rejected under 35 U.S.C. §103 as being unpatentable over NCBI Reference Sequence: NZ_APMH01000026.1 (Accession NZ_APMH01000026 Region: 51561..52344; 4/1/2017) in view of Blanchard (US 2010/0105114 Al), Kudoh (Kudoh et al. Proc. Nadl. Acad. Sci. USA Vol. 82, pp. 2665-2668, May 1985), Connor (Connor et al. Scientific Reports 9.1 (2019): 13722) and Hatt and Youngman (Hatt and Youngman. Journal of Bacteriology 182.24 (2000): 6975-6982), as applied to claim 1, and further in view of Lee (Lee et al. mBio 7(3):e00743-16. doi:10.1128/mBio.00743-16). Regarding claim 30, the modification explained in the rejection of claim 1 provides the claimed single-base-pair mutation in the sporulation-control gene, the nucleotide sequence of SEQ ID NO:1, and the resulting truncated transcription factor. Blanchard teaches introducing mutations into clostridial cells and describes replacement-type mutations prepared using PCR with mismatched primers [0083]. Thus, the combined teachings provide a method of producing the claimed mutant strain, rather than merely identifying an existing strain. Lee supplies additional teachings concerning cultivation and harvesting of C. tyrobutyricum. Specifically, Lee describes growing C. tyrobutyricum in 2× YTG medium and harvesting the cells at late exponential phase [p. 9, right column, “Isolation of genomic DNA and genome sequencing,” first paragraph]. Although Lee harvests those cells for genomic-DNA isolation, the disclosed cultivation and harvesting steps provide a known method of obtaining C. tyrobutyricum cells from an exponentially growing culture. It would have been obvious to cultivate the modified C. tyrobutyricum strain using the known cultivation procedure and harvest the resulting cells to obtain the isolated mutant bacterium. The artisan would have been motivated to do so to propagate and recover the strain produced by the mutagenesis step. Connor provides additional support for expecting that a spo0A nonsense mutant could remain capable of vegetative growth: the nonsporulating isolates did not exhibit a statistically significant difference in growth rate from their corresponding sporulating isolates [p. 3, paragraph 4]. Accordingly, the combined teachings support providing a culture, creating the claimed mutation, cultivating the resulting mutant during exponential growth, and harvesting the asporogenous bacteria. Regarding claims 31-32, Blanchard teaches introducing mutations through exposure to chemical agents, including nitrous acid, hydroxylamine, acridine dyes, and ethidium bromide and UV radiation [0092]. It would have been obvious to use a known chemical mutagen or UV radiation as a known alternative mutagenesis technique to generate sporulation-deficient mutants and screen for the desired phenotype of having altered sporulation activity. Regarding claim 33, Blanchard expressly teaches screening mutagenized clostridial cells for altered sporulation activity, including mutants blocked at stages 0 or 1 that do not initiate sporulation [0092]. Connor likewise tests recovered cells for sporulation by comparing viable counts before and after alcohol-shock treatment [p. 3, paragraph 3; Fig. 3]. It would have been obvious to screen a sample of the harvested mutant bacteria for an asporogenous phenotype to confirm that the intended disruption of sporulation had been achieved. Regarding claim 34, Hatt and Youngman teach determining sporulation frequency by comparing the number of chloroform-resistant spores with the total viable-cell count before chloroform treatment. The assay includes incubation with chloroform followed by dilution and plating [Materials and Methods, “Sporulation frequency assay,” first paragraph; Table 3]. It would have been obvious to employ this known differential-survival assay when screening the harvested bacteria to distinguish spore-forming cultures from cultures exhibiting the intended asporogenous phenotype. The chloroform-treatment alternative expressly recited in claim 34 is thereby provided. Conclusion No claims allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIFFANY N GROOMS whose telephone number is (571)272-3771. The examiner can normally be reached M-F 830-530. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer Dunston can be reached at 571-272-2916. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TIFFANY NICOLE GROOMS/Examiner, Art Unit 1637 /Jennifer Dunston/Supervisory Patent Examiner, Art Unit 1637
Read full office action

Prosecution Timeline

Mar 14, 2023
Application Filed
Oct 20, 2025
Non-Final Rejection mailed — §103, §112
Feb 08, 2026
Response Filed
Jun 30, 2026
Final Rejection mailed — §103, §112
Sep 16, 2026
Request for Continued Examination
Sep 18, 2026
Response after Non-Final Action
Sep 30, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760331
CAS12 PROTEINS AND USES THEREOF
1y 1m to grant Granted Oct 13, 2026
Patent 12746295
DCAS13-MEDIATED THERAPEUTIC RNA BASE EDITING FOR IN VIVO GENE THERAPY
3y 11m to grant Granted Sep 29, 2026
Patent 12729386
COMPOSITIONS AND PRODUCTION OF NICKED CLOSED-ENDED DNA VECTORS
4y 9m to grant Granted Sep 08, 2026
Patent 12617832
GENETIC ENGNEERING OF B CELL RECEPTORS AND USES THEREOF IN ANTIGEN-INDUCED ANTIBODY SECRETION
5y 1m to grant Granted May 05, 2026
Patent 12577574
ULTRASPECIFIC RIBOREGULATORS HAVING ROBUST SINGLE-NUCLEOTIDE SPECIFICITY AND IN VITRO AND IN VIVO USES THEREOF
2y 10m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
58%
Grant Probability
99%
With Interview (+46.4%)
High
PTA Risk
Based on 186 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month